J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD)
Rajeev Kumar, Daniel O Claassen, Ann Mongan, Benjamin Hoehn, Ping Lin, Ellen Cahir-Mcfarland, Lori Taylor, Priya Chandra, Ted Yednock, Henk-André Kroon
Journal of Neurology, Neurosurgery & Psychiatry Sep 2022, 93 (Suppl 1) A96-A97; DOI: 10.1136/jnnp-2022-ehdn.258